Panitumumab Emerges as Viable Alternative to Cetuximab in BRAF-Mutated Colorectal Cancer Treatment
Key Insights
A multicenter study demonstrates that switching from cetuximab to panitumumab during encorafenib therapy maintains clinical efficacy in BRAF V600E-mutated metastatic colorectal cancer (search) patients who experience infusion-related reactions (search).
The encorafenib plus panitumumab combination achieved an 85% disease control rate and 25% objective response rate, with median progression-free survival of 6.2 months and overall survival of approximately 11 months.
No infusion-related reactions (search) occurred with panitumumab, and the safety profile was manageable with mostly grade 1-2 adverse events, supporting its use as an alternative EGFR (search) inhibitor in this aggressive cancer subtype.
A new international multicenter analysis provides compelling evidence that panitumumab can effectively replace cetuximab in combination with encorafenib for patients with BRAF V600E-mutated metastatic colorectal cancer (search) who experience infusion-related reactions (search). The study, published in Clinics and Research in Hepatology and Gastroenterology, represents the largest real-world series to date examining this therapeutic switch.
Clinical Challenge Addressed
BRAF V600E-mutated metastatic colorectal cancer (search) represents a particularly aggressive subtype, accounting for approximately 8-10% of all metastatic colorectal cancer (search) cases. These tumors are associated with poor prognosis and limited sensitivity to conventional chemotherapy. While the BEACON CRC trial established encorafenib plus cetuximab as the standard of care, cetuximab can cause infusion-related reactions (search) in 2-5% of patients, with some reactions being life-threatening and requiring treatment discontinuation.
This creates a significant clinical dilemma, as BRAF (search) inhibition in colorectal cancer requires concomitant EGFR (search) blockade to achieve meaningful antitumor activity.
Study Design and Patient Population
The retrospective analysis included 20 patients with BRAF V600E-mutated metastatic colorectal cancer (search) across 12 centers in four countries. The median age was 66 years, with most patients having right-sided primary tumors and one quarter having dMMR/MSI disease. The majority were treated in the second-line setting.
Nineteen patients initially started encorafenib-cetuximab therapy and switched to encorafenib-panitumumab at cycle 2 or 3 following a cetuximab-related infusion reaction, predominantly grade 3-4 events occurring most often during the first infusion. One patient received encorafenib-panitumumab upfront by choice.
Efficacy Results
The encorafenib-panitumumab combination demonstrated clinically meaningful antitumor activity. The objective response rate reached 25%, while the disease control rate achieved 85%. Among the 20 patients, five achieved partial responses, 12 had stable disease, and three experienced progressive disease.
With a median follow-up of 15 months, the median progression-free survival was 6.2 months, and median overall survival reached 10.97 months (approximately 11 months). These outcomes are broadly comparable to historical results reported with encorafenib-cetuximab in the BEACON trial, though the authors acknowledge the limitations of retrospective and cross-trial comparisons.
Safety Profile
The safety profile of encorafenib-panitumumab proved manageable, with any-grade adverse events occurring in 75% of patients, mostly grade 1-2 in severity. The most frequent adverse events were skin rash (60%) and diarrhea (25%), followed by asthenia and hypomagnesemia (10% each). Arthralgia, nausea, and liver enzyme elevation were also reported.
Notably, no infusion-related reactions (search) were observed with panitumumab, and no treatment-related deaths occurred. Only one patient discontinued encorafenib-panitumumab due to toxicity, demonstrating the combination's tolerability.
Clinical Implications
The findings support encorafenib-panitumumab as a valid alternative therapeutic option for patients with BRAF V600E-mutated metastatic colorectal cancer (search) who cannot continue cetuximab due to infusion-related reactions (search). The combination appears to preserve the clinical benefit of dual BRAF (search) and EGFR (search) inhibition while eliminating the risk of recurrent infusion reactions.
The results reinforce the importance of maintaining EGFR (search) blockade in BRAF (search)-mutated colorectal cancer and provide clinicians with a viable treatment option when cetuximab becomes unsuitable. The authors note that prospective studies and additional real-world data will be important to further define the role of this combination, including potential use in earlier lines of therapy.